COMMUNIQUÉS West-GlobeNewswire

Notice to convene annual general meeting 2018 of GN Store Nord
19/02/2018
Please find enclosed notice of GN Store Nord A/S’ annual general meeting 2018, including the complete proposals for the agenda. For further information, please contact: Investors and analysts Peter Justesen VP – [...]
The American Health Council Names Gilberto Alvarado, MSN, CNP, FNP-BC, BSN, RN to Board of Nurses
19/02/2018
NEW YORK, Feb. 19, 2018 (GLOBE NEWSWIRE) -- Gilberto “Gil” Alvarado, MSN, CNP, FNP-BC, BSN, RN is named to the American Health Council’s Board of Nurses for his impeccable contributions to the nursing field, both in a [...]
Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and Operating Results
19/02/2018
BOTHELL, Wash., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
19/02/2018
FIT Biotech Oy Company release February 19, 2018 at 2:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]
Novo Nordisk A/S - Share repurchase programme
19/02/2018
Bagsværd, Denmark, 19 February 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Notice of Annual General Meeting
19/02/2018
Valby, Denmark, 2018-02-19 09:04 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 19 February 2018 – Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: Tuesday, 20 March 2018 at 10:00 am The [...]
Oasmia Pharmaceutical’s Docecal program achieves significant development milestone
19/02/2018
Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer. Uppsala, Sweden, February 19, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a [...]
Bone Therapeutics SA completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®
19/02/2018
Press release Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB ® Efficacy and safety results expected in mid-2019 Promising interim efficacy and safety data already reported [...]
Bone Therapeutics annonce le recrutement du dernier patient de son étude de Phase IIA dans la fusion vertébrale avec ALLOB®
19/02/2018
Communiqué de presse Bone Therapeutics annonce le recrutement du dernier patient de son étude de Phase IIA dans la fusion vertébrale avec ALLOB ® Résultats d'efficacité et de sécurité attendus mi-2019 Données [...]
MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
19/02/2018
LA JOLLA, Calif., Feb. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology
18/02/2018
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM ), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the [...]
AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
17/02/2018
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB ), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation [...]
TLC Files Registration Statement for Proposed Initial Public Offering
17/02/2018
TAIPEI, Taiwan, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel [...]
Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
17/02/2018
MOR106 was generally well tolerated in atopic dermatitis (AD) patients 83% of patients (5 out of 6) at the highest dose reached at least 50% improvement per the atopic dermatitis area and severity index (EASI-50) at [...]
ChromaDex Chairman Stephen Allen Will Retire from Board of Directors
16/02/2018
IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ: CDXC ), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age is announcing [...]
OncBioMune Provides Update on Market Activity
16/02/2018
BATON ROUGE, La., Feb. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary [...]
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
16/02/2018
Two thirds of patients on Cosentyx ® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/<=2/<=3 responses were [...]
Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals
16/02/2018
MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX ), a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet® ( [...]
HydRx Farms Ltd. (d/b/a Scientus Pharma Inc.) Announces Completion of its $15.8 Million Private Placement Offering of Common Shares
16/02/2018
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- [...]

Pages